17-61744432-CTT-C
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_032043.3(BRIP1):βc.2255_2256delβ(p.Lys752ArgfsTer12) variant causes a frameshift, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000434 in 1,613,142 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_032043.3 frameshift, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRIP1 | NM_032043.3 | c.2255_2256del | p.Lys752ArgfsTer12 | frameshift_variant, splice_region_variant | 15/20 | ENST00000259008.7 | NP_114432.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRIP1 | ENST00000259008.7 | c.2255_2256del | p.Lys752ArgfsTer12 | frameshift_variant, splice_region_variant | 15/20 | 1 | NM_032043.3 | ENSP00000259008 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152000Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251052Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135652
GnomAD4 exome AF: 0.0000445 AC: 65AN: 1461142Hom.: 0 AF XY: 0.0000358 AC XY: 26AN XY: 726826
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152000Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74202
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 02, 2022 | This variant deletes 2 nucleotides in exon 15 of the BRIP1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals with breast cancer (PMID: 17033622, 26681682, 26976419) and ovarian cancer (PMID: 26315354, 26681312, 29368626), as well as in an individual affected with Fanconi anemia (PMID: 16116423). This variant has been identified in 3/251052 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRIP1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 28, 2021 | The c.2255_2256delAA pathogenic mutation, located in coding exon 14 of the BRIP1 gene, results from a deletion of two nucleotides at nucleotide positions 2255 to 2256, causing a translational frameshift with a predicted alternate stop codon (p.K752Rfs*12). This mutation was seen in conjunction with a second BRIP1 alteration in a patient with Fanconi anemia complementation group J (Levitus M et al. Nat. Genet. 2005 Sep;37:934-5). It has also been seen in patients with breast and/or ovarian cancer (Ramus SJ et al. J Natl Cancer Inst. 2015 Nov;107; Susswein LR et al. Genet. Med. 2016 Aug;18:823-32; Tung N et al. J Clin Oncol. 2016 May;34:1460-8; Carter NJ et al. Gynecol Oncol. 2018 12;151:481-488; Weber-Lasalle N et al. Breast Cancer Res. 2018 Jan;20(1):7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Sep 02, 2021 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 27, 2019 | This variant alters the translational reading frame of the BRIP1 mRNA and causes the premature termination of BRIP1 protein synthesis. This variant has been reported in individuals with breast cancer, ovarian cancer, and Fanconi Anemia complementation group J (FA-J) in the published literature (PMID: 26976419 (2016), 26681312 (2018), 26681312 (2015), 16116423 (2005)). Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 04, 2024 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (PMID: 17033622, 26315354, 26976419, 29368626, 32359370); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28152038, 26681312, 19763819, 26315354, 17033622, 26976419, 29308099, 26681682, 29368626, 20346647, 30322717, 16116423, 32359370, 26689913, 29625052, 29922827, 28888541, 34326862, 34887416, 34308104, 35626031, 36451132) - |
Familial cancer of breast Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 28, 2023 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 24, 2024 | - - |
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 03, 2024 | This sequence change creates a premature translational stop signal (p.Lys752Argfs*12) in the BRIP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRIP1 are known to be pathogenic (PMID: 16116423, 17033622, 21964575). This variant is present in population databases (rs730881649, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with ovarian cancer or breast cancer and Fanconi anemia (PMID: 16116423, 26315354, 26681312, 26681682, 26976419). This variant is also known as c.2255_2256delTT. ClinVar contains an entry for this variant (Variation ID: 182372). For these reasons, this variant has been classified as Pathogenic. - |
Ovarian neoplasm;C1836860:Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Dec 18, 2017 | - - |
Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 08, 2019 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 18, 2016 | Variant summary: The variant of interest causes a frameshift mutation resulting in a premature termination codon, a known mechanism for disease, as these types of variants are predicted to cause transcript degradation through nonsense mediated decay or produce a truncated protein. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/121342 (1/60679), which does not exceed the predicted maximum expected allele frequency for a pathogenic BRIP1 variant of 1/16000. In addition, this observation needs to be cautiously considered due to the cohort including individuals that could harbor a BRIP1 phenotype. The variant of interest has been reported in affected individuals with varying phenotypes BrC, OvC and FANCJ, including the variant of interest segregating with disease (BrC) within one family (Seal_2006). In addition, multiple reputable clinical laboratories cite the variant with a classification of "pathogenic." Therefore, taking all available lines of evidence into consideration, the variant of interest is classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at